Glioma-targeted therapeutics: computer-aided drug design prospective

P Poonan, C Agoni, MAA Ibrahim, MES Soliman - The protein journal, 2021 - Springer
Amongst the several types of brain cancers known to humankind, glioma is one of the most
severe and life-threatening types of cancer, comprising 40% of all primary brain tumors …

Personalized quantitative models of NAD metabolism in hepatocellular carcinoma identify a subgroup with poor prognosis

A Chedere, M Mishra, O Kulkarni, S Sriraman… - Frontiers in …, 2022 - frontiersin.org
Cancer cells are known to undergo metabolic adaptation to cater to their enhanced energy
demand. Nicotinamide adenine dinucleotide (NAD) is an essential metabolite regulating …

Identification of a co‐target for enhancing efficacy of sorafenib in HCC through a quantitative modeling approach

M Mishra, P Jayal, AA Karande… - The FEBS Journal, 2018 - Wiley Online Library
Sorafenib (SFB), a multi‐kinase inhibitor, is the only approved drug for treating
hepatocellular carcinoma (HCC). However, SFB shows low efficacy in many cases. HCC …

Nicotinamide adenine dinucleotide+ metabolism biomarkers in malignant gliomas

M Jiménez-García, E Verdugo-Sivianes… - Cancer …, 2016 - search.proquest.com
Gliomas are highly metabolically active tumors. Cancer metabolism is currently of great
interest to researchers. Nicotinamide adenine dinucleotide (NAD) is central in cell …

[HTML][HTML] Optimización del ensayo de inhibición de la nicotinamida/nicotinato mononucleótido adenililtransferasa de Leishmania braziliensis

CG Granados-Ramírez… - Revista de la …, 2021 - scielo.org.co
La nicotinamida/nicotinato mononucleótido adenililtransferasa (NMNAT, EC 2.7. 7.1/18)
desempeña una función central en la síntesis del dinucleótido de adenina y nicotinamida …